Comparative Pharmacology
Head-to-head clinical analysis: NUTROPIN AQ NUSPIN versus SEROSTIM LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTROPIN AQ NUSPIN versus SEROSTIM LQ.
NUTROPIN AQ NUSPIN vs SEROSTIM LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathway, leading to increased IGF-1 production and promotion of linear growth, protein synthesis, and lipolysis.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
Subcutaneous injection 0.16-0.24 mg/kg/week divided into 6-7 daily doses.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
None Documented
None Documented
Terminal half-life: 3.9–4.3 hours (subcutaneous); supports daily dosing
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Renal: >90% as intact peptide; minor biliary/fecal elimination (<5%)
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Category C
Category C
Growth Hormone
Growth Hormone